A Phase 1 Study of LY2875358 in Japanese Patients With Advanced Malignancies
Phase of Trial: Phase I
Latest Information Update: 02 May 2017
At a glance
- Drugs Emibetuzumab (Primary) ; Erlotinib; Gefitinib
- Indications Lymphoma; Non-small cell lung cancer; Solid tumours
- Focus Adverse reactions
- Sponsors Eli Lilly
- 04 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 02 Jun 2014 Planned End Date changed from 1 Oct 2014 to 1 Aug 2014 as reported by ClinicalTrials.gov.
- 02 Jun 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.